Regeneron's REGN7508 demonstrated superior efficacy to enoxaparin in preventing venous thromboembolism (VTE) after knee surgery, with a 7% VTE event rate compared to 21%.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.